- Big Pharma deals may lie ahead in 2013
Pfizer and Merck are among the drugmakers with enough cash on hand to invest $10 billion or more in mergers and acquisitions this year. However, expiring patents on blockbuster drugs, more muscular biotechnology companies and stronger competition might impede Big Pharma's ability to conclude large deals, an Ernst & Young analysis found. Bloomberg (1/7), PharmaTimes (U.K.) (1/7)       | Review 2012: Great Year on Capital Markets; Fundraising a Challenge | | Last year the prevailing economic woes did not prove to be much of an impediment for biopharmaceutical companies in their quest to generate capital with a total of $24.8 billion raised. However, the financial uncertainties in Europe, a weak domestic economy, a U.S. presidential election and the "fiscal cliff" all contributed toward making it a challenging environment. Find out the details. |  |
| Health Care & Policy |  |  | | - EU clears expanded use of Pfizer's Prevenar 13 vaccine
The European Commission approved the use of Pfizer's pneumococcal conjugate vaccine, Prevenar 13, in children ages 6 to 17. The vaccine prevents diseases caused by the bacterium Streptococcus pneumoniae. Children belonging to this age group who haven't previously received the vaccine may get a single dose of Prevenar 13, Pfizer said. Reuters (1/8) | Company & Financial News | | | | - TVAX raises $2 million for cancer drug R&D
TVAX Biomedical, a clinical-stage firm working on a targeted cell-based cancer immunotherapy, secured $2 million in private financing. The money will go toward research and development. "We look forward to putting this latest funding to work and systematically achieving those key clinical milestones that lie ahead for the TVAX immunotherapy platform," new CEO Philip Haworth said. American City Business Journals/Kansas City, Mo. (1/8) | Food & Agriculture | | | | | Industrial & Environmental | | | | - Novozymes, partner get $2.5M federal grant for enzyme project
The Department of Energy has issued a $2.5 million grant for a two-year project by Novozymes and partner MBI aimed at identifying more cost-effective enzymes for the conversion of corn stover into fuel. Under the "SynTec" project, the companies will test for the most efficient enzymes using pretreated agricultural waste. DomesticFuel.com (1/7) | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | If you want to test your memory, try to recall what you were worrying about one year ago today."
--E. Joseph Cossman,
American entrepreneur and inventor  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, January 08, 2013
- Monday, January 07, 2013
- Friday, January 04, 2013
- Thursday, January 03, 2013
- Wednesday, January 02, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment